This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Allergan plc, Dublin, Ireland.
Reference
Murray B, et al. Cost-effectiveness of overactive bladder treatments: from the US payer perspective. Journal of Comparative Effectiveness Research : 4 Dec 2018. Available from: URL: https://doi.org/10.2217/cer-2018-0079
Rights and permissions
About this article
Cite this article
OnabotA best treatment option for overactive bladder. PharmacoEcon Outcomes News 818, 21 (2018). https://doi.org/10.1007/s40274-018-5519-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5519-5